Eli Lilly And Company (LLY)
NYSE:LLY
Want to see LLY full AI Analyst Report?
Top Page
Eli Lilly & Co
(NYSE:LLY)
Select Model
Select Model
Rating:78Outperform
Price Target:
$1,065.00
▲(14.88% Upside)
Action:ReiteratedDate:05/01/26
The score is driven primarily by outstanding financial performance and a strongly positive earnings call with raised guidance. Offsetting factors are a premium valuation and mixed/neutral technical signals, with leverage and pricing pressure remaining key risks to monitor.
Positive Factors
Accelerating revenue and margin expansion
Sustained, multi-year revenue acceleration and materially higher net margins indicate durable demand for Lilly’s branded medicines. High gross margins and improved net margin provide structural cash flow to fund R&D, commercialization and competitive positioning even if market growth moderates.
Negative Factors
Elevated financial leverage
Material leverage increases financial risk if top‑line momentum or pricing power weakens. Higher debt limits flexibility for large, opportunistic M&A and raises sensitivity to interest costs or capital markets disruption, potentially constraining strategic moves during downturns.
Read all positive and negative factors
Positive Factors
Negative Factors
Accelerating revenue and margin expansion
Sustained, multi-year revenue acceleration and materially higher net margins indicate durable demand for Lilly’s branded medicines. High gross margins and improved net margin provide structural cash flow to fund R&D, commercialization and competitive positioning even if market growth moderates.
Read all positive factors
Eli Lilly & Co (LLY) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$883.03B
Dividend Yield0.58%
Average Volume (3M)2.74M
Price to Earnings (P/E)27.8
Beta (1Y)0.69
Revenue Growth47.44%
EPS Growth130.02%
CountryUS
Employees47,000
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - General
Share Statistics
EPS (TTM)8.55
Shares Outstanding944,818,900
10 Day Avg. Volume2,553,212
30 Day Avg. Volume2,742,315
Financial Highlights & Ratios
PEG Ratio0.49
Price to Book (P/B)36.37
Price to Sales (P/S)14.81
P/FCF Ratio107.56
Enterprise Value/Market Cap0.95
Enterprise Value/Revenue11.62
Enterprise Value/Gross Profit13.92
Enterprise Value/Ebitda25.34
Forecast
1Y Price Target
$1,254.68Price Target Upside35.34% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering21
EPS Forecast (FY)35.47
Revenue Forecast (FY)$83.34B
Eli Lilly & Co Business Overview & Revenue Model
Company Description
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 7...
How the Company Makes Money
Lilly makes money primarily by selling patented, branded prescription medicines. Revenue is generated when Lilly sells its drugs to wholesalers, pharmacies, hospitals, and other distributors (directly or through third parties), and those products ...
Eli Lilly & Co Key Performance Indicators (KPIs)
Any
Revenue by Geography
Maps revenue across countries and regions to show market concentration and diversification. A heavy tilt toward a single market increases vulnerability to local policy or pricing shifts, while broad geographic growth suggests more durable sales and opportunity to offset regional downturns.
Maps revenue across countries and regions to show market concentration and diversification. A heavy tilt toward a single market increases vulnerability to local policy or pricing shifts, while broad geographic growth suggests more durable sales and opportunity to offset regional downturns.
Data provided by:
The Fly
The FlyEli Lilly & Co Earnings Call Summary
Earnings Call Date:Apr 30, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 04, 2026
Earnings Call Sentiment Positive
The call conveyed a strongly positive operational and financial picture: exceptional revenue and earnings growth, raised guidance, robust international momentum for incretins, successful clinical readouts (including cardiovascular safety for Foundayo), an ambitious pipeline with 42 active Phase III programs, and multiple strategic acquisitions to broaden capabilities. The principal concerns are meaningful pricing pressure (expected low-to-mid-teens headwind), increased marketing and R&D spend, access variability (Medicaid and payer coverage), early-stage uncertainty around Foundayo's ultimate contribution, and competitive/generic dynamics in some markets. On balance, the highlights materially outweigh the lowlights.Positive Updates
Strong Top-Line Revenue Growth
Revenue grew 56% year-over-year in Q1 2026 compared to Q1 2025; updated full-year revenue guidance raised by $2 billion at each end to $82 billion–$85 billion (midpoint = ~28% growth vs 2025).
Negative Updates
Price Pressure and Expected Full-Year Headwind
U.S. price declined ~7% in Q1 (would be ~10% excluding a one-time adjustment); company expects price to be a headwind in the low-to-mid teens for the full year, exerting pressure on gross margin and net pricing dynamics.
Read all updates
Q1-2026 Updates
Positive
Negative
Strong Top-Line Revenue Growth
Revenue grew 56% year-over-year in Q1 2026 compared to Q1 2025; updated full-year revenue guidance raised by $2 billion at each end to $82 billion–$85 billion (midpoint = ~28% growth vs 2025).
Read all positive updates
Company Guidance
Lilly raised its 2026 guidance, increasing the top and bottom of the full‑year revenue range by $2.0 billion to $82–$85 billion (midpoint ≈ 28% growth vs. 2025) and boosting non‑GAAP EPS guidance to $35.50–$37 (a $2.00 lift to both ends); it now expects a non‑GAAP performance margin of 47.0%–48.5%, sees price as a headwind in the low‑ to mid‑teens for the year, and left its tax rate unchanged. Management said the upward revision reflects strong Q1 results — revenue +56% y/y, Q1 non‑GAAP EPS $8.55, gross margin 82.6%, marketing/selling/admin expenses +19%, and R&D +28% — driven by robust performance of Mounjaro, semaglutide/SEB and other key products.Eli Lilly & Co Financial Statement Overview
Summary
Income Statement
93
Very Positive
Balance Sheet
72
Positive
Cash Flow
83
Very Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 72.25B | 65.18B | 45.04B | 34.12B | 28.54B | 28.32B |
| Gross Profit | 60.33B | 54.62B | 36.62B | 27.04B | 21.91B | 21.01B |
| EBITDA | 33.13B | 27.94B | 15.23B | 8.57B | 8.66B | 8.04B |
| Net Income | 25.27B | 20.64B | 10.59B | 5.24B | 6.24B | 5.58B |
Balance Sheet | ||||||
| Total Assets | 116.58B | 112.48B | 78.71B | 64.01B | 49.49B | 48.81B |
| Cash, Cash Equivalents and Short-Term Investments | 5.28B | 7.27B | 3.42B | 2.93B | 2.21B | 3.91B |
| Total Debt | 43.37B | 42.50B | 33.64B | 25.23B | 16.24B | 16.88B |
| Total Liabilities | 85.38B | 85.94B | 64.44B | 53.14B | 38.71B | 39.65B |
| Stockholders Equity | 31.20B | 26.54B | 14.19B | 10.77B | 10.65B | 8.98B |
Cash Flow | ||||||
| Free Cash Flow | 13.58B | 8.97B | 414.30M | -3.15B | 4.60B | 5.39B |
| Operating Cash Flow | 20.48B | 16.81B | 8.82B | 4.24B | 7.59B | 7.37B |
| Investing Cash Flow | -11.54B | -10.97B | -9.30B | -7.15B | -3.76B | -2.87B |
| Financing Cash Flow | -7.06B | -2.21B | 1.23B | 3.50B | -5.41B | -4.13B |
Eli Lilly & Co Technical Analysis
Neutral
927.03
Price Trends
973.14
Negative
1013.43
Negative
903.41
Positive
Market Momentum
-13.13
Negative
46.72
Neutral
31.60
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LLY, the sentiment is Neutral. The current price of 927.03 is above the 20-day moving average (MA) of 920.13, below the 50-day MA of 973.14, and above the 200-day MA of 903.41, indicating a neutral trend. The MACD of -13.13 indicates Negative momentum. The RSI at 46.72 is Neutral, neither overbought nor oversold. The STOCH value of 31.60 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for LLY.
Eli Lilly & Co Risk Analysis
Eli Lilly & Co disclosed 16 risk factors in its most recent earnings report. Eli Lilly & Co reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Eli Lilly & Co Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | $883.03B | 27.81 | 97.85% | 0.58% | 47.44% | 130.02% | |
71 Outperform | $553.30B | 28.32 | 26.26% | 2.50% | 7.87% | -3.56% | |
71 Outperform | £216.31B | 24.41 | 23.00% | 1.53% | 4.64% | 26.75% | |
67 Neutral | $270.34B | 23.10 | 32.80% | 2.87% | 5.60% | 9.68% | |
66 Neutral | $269.66B | -17.53 | 36.19% | 3.12% | 2.84% | ― | |
57 Neutral | $373.77B | 137.98 | -361.58% | 2.87% | 9.50% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
LLY
Eli Lilly & Co
963.33
145.76
17.83%
JNJ
Johnson & Johnson
227.19
75.30
49.58%
MRK
Merck & Company
112.16
31.90
39.74%
NVS
Novartis
146.57
34.47
30.76%
ABBV
AbbVie
206.60
14.39
7.49%
GB:AZN
AstraZeneca
13,512.00
2,942.22
27.84%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.